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It is reasonable to recommended 
intrapleural alteplase for loculated pleural 
effusions 
TRICIA FERNANDEZ, Wayne State University, Detroit, MI, tfernan1@hfhs.org  
 
ABSTRACT A critical appraisal and clinical application of Thommi G, Shehan J, Robison K, Christensen M, Backemeyer L, 
McLeay M. A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of 
alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions. Respir Med. 2012;17(2):716-723. doi: 
10.1016/j.rmed.2012.02.005 
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Clinical Context 
A 46-year-old male with stage 4 adenocarcinoma of the lung and malignant effusion, managed with intrapleural 
catheter, was admitted for treatment of catheter-related infection of his effusion. Due to concerns about the cuff 
of the catheter acting as a reservoir for infectious agents, as well as patient complaints of pain at the catheter site, 
the catheter was removed. IV antibiotics were administered and the patient was advised to have a pigtail catheter 
placed to drain the infected intrapleural fluid. However, the patient feared pain regarding the pigtail catheter 
insertion and desired to be discharged home on IV antibiotics. By the time the patient agreed to catheter 
placement on day seven of admission, the fluid had developed many loculations and little fluid could be drained. 
Due to the patient’s stable clinical picture and his strong desire to return to his family, it was decided that the 
pigtail catheter be removed and to discharge him home on IV nafcillin with instructions to monitor temperatures 
and return if fever recurred. The patient was so intent upon discharge that further interventions were not given 
much consideration. However, his case raises the question of whether administration of thrombolytics through the 
catheter could have broken down the loculations and allowed for resolution of the complicated pleural effusion 
prior to discharge. 
Clinical Question 
Does administration of intrapleural thrombolytics lead to better resolution of a loculated effusion compared to simple drainage with 
standard medical therapy? 
Research Article 
Thommi G, Shehan J, Robison K, Christensen M, Backemeyer L, McLeay M. A double blind randomized cross over trial comparing 
rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated 
parapneumonic effusions. Respir Med. 2012;17(2):716-723. doi: 10.1016/j.rmed.2012.02.005. 
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Literature Review 
The relevant literature was found via PubMed and UpToDate searches with the search terms “loculated pleural effusion” and 
“intrapleural thrombolytics.” These studies are split between one large trial (N = 454) that concludes that thrombolytics should not 
be used in the treatment of pleural effusion1 and several smaller studies (N ≤ 100) in favor of the use of thrombolytics in the 
treatment of pleural effusion2-10. There are also three meta-analyses of the randomized, placebo-controlled trials written on this 
topic, all of which conclude that intrapleural thrombolytics likely reduce the need for surgical intervention in some patients, but that 
the data are heterogenous11-13.   
The large study whose conclusions advise against the use of thrombolytics is a double-blind trial in which 454 patients with pleural 
infection were randomly sorted to receive either intrapleural streptokinase or placebo. The primary end point, the number of 
patients who died or ended up needing surgical drainage after three months, was found to be comparable between the two groups, 
with a relative risk of 1.14 (95% CI 0.85 to 1.54; p = 0.43). However, the inclusion criteria for the study—any patient with evidence of 
infected pleural effusion—did not sufficiently narrow down the subject pool to those who were ideal candidates for thrombolytic 
therapy. The main rationale for the use of thrombolysis in this context is to break down septations or loculations that prevent free 
flow of fluid through the catheter. By including patients in the study regardless of evidence of blockage or loculation, the authors 
may have diluted the trial with patients who were not legitimate candidates for the therapy under study, rendering the trial 
incapable of detecting the true effect of thrombolytics in patients who could benefit from them. At the request of peer reviewers, as 
noted by the authors, a post-hoc analysis of patients both with and without baseline radiographic evidence of loculation was 
performed, which likewise concluded that there was no difference between the treatment and placebo arms14. However, the trial 
was clearly not designed for this analysis, and it resulted in the researchers using a poor imaging modality to assess for loculation. 
Instead of more suitable modalities, such as thoracic ultrasound or computed tomographic (CT) scanning, investigators were forced 
to rely on baseline frontal radiographs, which are unsuited to characterizing the features of pleural effusions15. Additionally, there 
were only 84 patients with loculations in both groups combined, suggesting that the subgroup was underpowered to find a 
difference if one existed. This detracts from the validity of the subgrouping and, by extension, the value of the post-hoc analysis. 
Of the nine studies that support the use of thrombolytic therapy, five had no control arm; two were retrospective reviews of cases of 
intrapleural alteplase treatment2-3; two were single-arm prospective studies of similar cases4-5; one was a randomized trial 
comparing the efficacies of intrapleural streptokinase and intrapleural urokinase, without a control group6; two were single-center, 
randomized, placebo-controlled trials, using inclusion criteria that were too broad for this situation (patients were grouped together 
if they had either empyema or a complicated parapneumonic effusion, and only a subset of these patients had loculations)7-8; and 
the remaining two papers were both double-blind, randomized studies that included patients who had been diagnosed with 
multiloculated pleural effusions based on ultrasound and/or CT evidence9-10. Both of these last studies also required participants to 
have failed simple tube drainage, which may indicate a blockage of free flow. The larger of the two, N = 1009 (versus N = 3110), was 
selected for appraisal. This paper had only two patients with malignant parapneumonic pleural effusions, which underrepresents our 
patient. However, due to the lack of large randomized, controlled trials of intrapleural thrombolytics for patients with loculated 
malignant effusions, it was reasonable to approach our patient’s loculated effusion similarly to loculated effusions caused by 
infectious processes. 
Critical Appraisal 
The study being examined is a double blind randomized trial with two treatment arms. In the first arm of the trial, randomly-
assigned patients underwent three days of daily treatment with either intrapleural alteplase or placebo. Adequate response to 
treatment was evaluated by improvement on chest CT, though the major outcome variable was a reduction in surgical intervention. 
Subjects were determined to have failed treatment if pleural fluid had not decreased by 50% by the fourth day. Patients who did not 
respond were offered the opportunity to cross over into the second arm of the study, in which they would receive three days of the 
other treatment. Again, response was assessed by CT scan, using the same criterion of 50% resolution. Treatment was deemed 
successful if the effusions resolved and did not recur within six weeks (as determined by chest radiograph), thus eliminating the 
need for surgical intervention. 
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Patients were included in the study if they had either empyema (either pH < 7 OR pleural culture positive OR frank pus noted) or a 
complicated parapneumonic effusion (both exudate AND CT scan and ultrasound showed multiple loculations with a pneumonic 
process) and had failed to resolve their effusions with chest tube drainage and standard medical therapy. Patients with empyema 
and complicated parapneumonic effusion (CPE) underwent the same study but were analyzed in separate groupings. This allowed 
for isolated consideration of patients with loculations, as opposed to the larger study from the literature review. Patients were 
excluded if they were at increased risk for various bleeding complications, were below the age of 18, or were pregnant.  
Overall, adding across the two arms, 58/61 treatments (26 cross over) with alteplase were successful, versus 4/34 treatments (one 
cross over) with placebo (p < 0.001). Considering only the patients with loculated pleural effusions, 42/45 treatments (22 cross over) 
with alteplase were successful, versus 4/29 treatments (one cross over) with placebo (p < 0.001). 
Strengths of this study include the fact that, since this was a cross over study, some patients were able to serve as their own controls, 
thus reducing the opportunity for confounding. Also, the double-blinded nature of the study ensured that bias was not introduced 
into the study by the prior knowledge of the patients, physicians, or investigators. This includes the primary investigator, who read 
all chest radiographs and CT scans blindly. Weaknesses include the fact that this cross over study lacks uniformity within sequence 
by design; if patients clear their effusions in the first arm of the trial, they cannot cross over to receive the other treatment. This 
detracts from the ability of patients to serve as their own controls. There is also the inherent cross over study issue of the “wash-out 
period”—patients who failed initial treatment were crossed over the day after completion of the first arm, which may have allowed 
the placebo and alteplase treatments to affect each other. Although there is little concern for residual placebo affecting a 
subsequent alteplase treatment, it was possible for patients crossing from alteplase treatment to placebo treatment to have falsely 
elevated responses to the placebo as a result of insufficient clearance of the drug. The absolute size effect of efficacy for alteplase 
compared to placebo indicates the active treatment provided benefit. Finally, any study is limited by the population studied—in this 
case, participants tended to be older adults (age mean 64 ± 15), as well as predominately male (male to female ratio 37:21). This 
makes it more difficult to generalize the findings of this study to other demographics. 
This double blind randomized trial meets criteria for level 1b evidence according to the Oxford Centre for Evidence-Based Medicine 
Levels of Evidence. 
Based on the response ratios above, the number needed to treat (NNT) in the case of loculated effusions is 1.26, meaning that more 
than half of treated patients will see better outcomes on alteplase treatment versus a placebo control. For a calculation of a number 
needed to harm, it is best to look at the major adverse event associated with thrombolytic therapy, which is hemorrhage. In the 
treatment arm, two patients experienced bleeding during alteplase treatment, one of whom was removed from the trial, 
presumably to avoid further complications (both patients required transfusions; neither patient died). Therefore, among the total 
number of patients treated, this gives a rate of bleeding of 2/62. The number needed to harm (NNH) for bleeding = 31. 
Clinical Application 
When conveying this information to patients with loculated pleural effusions, it is important to note that this trial 
only applies to patients whose effusions were infectious in nature. In the patient described above, his pleural 
effusion was malignant in origin, so the conclusions of the paper must be extrapolated with caution. Patients 
should be told that, according to this study, the treatment is highly effective at resolving effusions, with a small risk 
of significant bleeding that may require transfusion. However, this is one study in a somewhat contested area of 
medicine, and patients should know that the collected evidence is not of the highest caliber. In addition, patients 
should be informed that the major alternative to this management is surgical debridement of the loculated 
effusion. Depending on how amenable patients are to surgery versus a more experimental but less invasive 
treatment, they may choose one option or the other. 
In the case of the patient in the Clinical Context, several factors contributed to pursuing antibiotic treatment 
versus more aggressive drainage interventions, chief among them being the patient’s wishes in the face of a short 
life-expectancy. This patient had spent much of the previous two months admitted to the hospital due to 
complications from his stage 4 adenocarcinoma. Allowing him to return home to his family on antibiotics was a 
quality of life decision as opposed to a purely medical one. However, this decision was not without its cost—an 
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increased risk of sepsis, possible expansion of the effusion, cumbersome temperature monitoring, and extended 
home IV antibiotic treatments were all negative consequences. If circumstances had been slightly different, it 
might have been of benefit to this patient to stay a few more days in the hospital and receive alteplase treatment 
before discharge. 
In order to learn more and further help future patients, it will be necessary to conduct more randomized 
controlled trials, specifically for malignant effusions. Such trials may require collaboration across multiple 
treatment centers in order to recruit enough patients. In doing this, it may be possible to establish intrapleural 
alteplase as a way to resolve loculated malignant effusions more effectively and rapidly, thus ensuring greater 
patient safety and decreased length of stay. 
Take-home points 
1.) Intrapleural alteplase infusion is probably an effective and relatively safe treatment for loculated pleural 
effusions 
2.) Large studies are most applicable if their inclusion criteria capture a clinically significant patient population 
3.) Every decision should weigh the evidence with the patient’s wishes and quality of life 
References 
1. Maskell N, Davies C, Nunn A, et al. U.K controlled trial of intrapleural streptokinase for pleural infection. N Engl J 
Med. 2005;352(9):865-874. doi: 10.1056/NEJMoa042473. 
2. Gervais D, Levis D, Hahn P, Uppot R, Arellano R, Mueller P. Adjunctive intrapleural tissue plasminogen activator administered via 
chest tubes placed with imaging guidance: effectiveness and risk for hemorrhage. Radiology. 2008;246(3):956-963. doi: 
10.1148/radiol.2463070235. 
3. Davies CW, Traill ZC, Gleeson FV, Davies RJ. Intrapleural streptokinase in the management of malignant multiloculated pleural 
effusions. Chest. 1999;115(3):729-33. doi: 10.1378/chest.115.3.729 
4. Zuckerman D, Reed M, Howington J, Moulton J. Efficacy of intrapleural tissue-type plasminogen activator in the treatment of 
loculated parapneumonic effusions. J Vasc Interv Radiol. 2009;20:1066-1069. doi: 10.1016/j.jvir.2009.04.067. 
5. Hsu LH, Soong TC, Feng AC, Liu MC. Intrapleural urokinase for the treatment of loculated malignant pleural effusions and 
trapped lungs in medically inoperable cancer patients. J Thorac Oncol. 2006; 1(5):460-7. doi: 10.1016/S1556-0864(15)31612-9 
6. Bouros D, Schiza S, Patsourakis G, Chalkiadakis G, Panagou P, Siafakas NM. Intrapleural streptokinase versus urokinase in the 
treatment of complicated parapneumonic effusions: a prospective, double-blind study. Am J Respir Crit Care Med. 
1997;155(1):291-5. doi: 10.1164/ajrccm.155.1.9001327 
7. Diacon A, Theron J, Schuurmans M, Van de Wal B, Bolliger C. Intrapleural streptokinase for empyema and complicated 
parapneumonic effusions. Am J Respir Crit Care Med. 2004;170:49-53. doi: 10.1164/rccm.200312-1740OC 
8. Davies RJ, Traill ZC, Gleeson FV. Randomised controlled trial of intrapleural streptokinase in community acquired pleural 
infection. Thorax. 1997;52(5):416-421. doi: 10.1136/thx.52.5.416 
9. Thommi G, Shehan J, Robison K, Christensen M, Backemeyer L, McLeay M. A double blind randomized cross over trial comparing 
rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated 
parapneumonic effusions. Respir Med. 2012;17(2):716-723. doi: 10.1016/j.rmed.2012.02.005 
10. Bouros D, Schiza S, Tzanakis N, Chalkiadakis G, Drositis J, Siafakas N. Intrapleural urokinase versus normal saline in the treatment 
of complicated parapneumonic effusions and empyema. Am J Respir Crit Care Med. 1999;159:37-42. doi: 
10.1164/ajrccm.159.1.9803094. 
11. Nie W, Liu Y, Ye J, et al. Efficacy of intrapleural instillation of fibrinolytics for treating pleural empyema and parapneumonic 
effusion: a meta-analysis of randomized control trials. Clin Respir J. 2014;8(3):281–291. doi: 10.1111/crj.12068 
12. Cameron RJ, Davies HR. Intra-pleural fibrinolytic therapy versus conservative management in the treatment of adult 
parapneumonic effusions and empyema. Cochrane Database Syst Rev. 2008;2: CD002312. doi: 
10.1002/14651858.CD002312.pub3 
13. Janda S, Swiston J. Intrapleural fibrinolytic therapy for treatment of adult parapneumonic effusions and empyemas: a systematic 
review and meta-analysis. Chest. 2012;142(2):401-11. doi: 10.1378/chest.11-3071 
FERNANDEZ T. It is reasonable to recommended intrapleural alteplase for loculated pleural 
effusions. Clin. Res. Prac. 2017;3(1):eP1162. doi: 10.22237/crp/1484092980 
 
VOL 3 ISS 1 / eP1162 / JANUARY 11, 2017  
doi: 10.22237/crp/1484092980 
 
 
 
ISSN: 2379-4550 
http://digitalcommons.wayne.edu/crp, © 2017 The Author(s) 
5 Licensed under Creative Commons Attribution Non-Commercial 4.0 
 
14. Maskell N, Davies C, Nunn A, et al. U.K controlled trial of intrapleural streptokinase for pleural infection [supplemental 
appendix]. N Engl J Med. 2005;352(9):865-874. doi: 10.1056/nejmoa042473 
15. Katikireddy CK. A trial of intrapleural streptokinase [letter]. N Engl J Med. 2005;352(2):2243-2245. doi: 
10.1056/NEJM200505263522118 
